Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
P/B ratio for Biogen Inc. (BIIB)
P/B ratio as of 2023: 2.53
According to Biogen Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.53. At the end of 2022 the company had a P/B ratio of 3.01.
P/B ratio history for Biogen Inc. from 1985 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.53 |
| 2022 | 3.01 |
| 2021 | 3.26 |
| 2020 | 3.69 |
| 2019 | 4.16 |
| 2018 | 4.73 |
| 2017 | 5.38 |
| 2016 | 5.11 |
| 2015 | 7.54 |
| 2014 | 7.42 |
| 2013 | 7.68 |
| 2012 | 5.00 |
| 2011 | 4.15 |
| 2010 | 3.13 |
| 2009 | 2.47 |
| 2008 | 2.40 |
| 2007 | 3.25 |
| 2006 | 2.33 |
| 2005 | 2.20 |
| 2004 | 3.27 |
| 2003 | 0.93 |
| 2002 | 3.18 |
| 2001 | 7.58 |
| 2000 | 25.48 |
| 1999 | 15.04 |
| 1998 | 4.82 |
| 1997 | 4.73 |
| 1996 | 3.59 |
| 1995 | 1.86 |
| 1994 | 0.21 |
| 1993 | 2.20 |
| 1992 | 4.20 |
| 1991 | 6.12 |
| 1990 | 11.58 |
| 1989 | 2.69 |
| 1988 | 16.54 |
| 1987 | 24.00 |
| 1986 | 16.45 |
| 1985 | 18.39 |